Lindsey Shapiro, PhD, science writer —

The use of the hormone vasopressin successfully stabilized symptoms associated with pulmonary hypertension (PH) in newborns, and avoided the need for more invasive treatment approaches in some infants, according to data from 10 cases. “Although our findings are exploratory and further research is needed to establish safety and efficacy,…

The leading causes of death among people with pulmonary hypertension (PH) differ by PH type, a Japanese study has found. When categorized using the World Health Organization (WHO) PH classification, those in group 1 died mostly from PH itself, those in group 3 died more often from…

High scores on a measure known as H2FPEF — which reflect an increased probability of dysfunction of the left ventricle (LV) of the heart — were associated with signs of LV impairment and a worse prognosis in patients with idiopathic pulmonary arterial hypertension (IPAH), a study found. Patients with…

Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). Developed through a collaboration of scientists at Anumana, Janssen Research and Development, and the Mayo Clinic, the artificial intelligence (AI)-powered algorithm is designed…

To celebrate World Pulmonary Hypertension Day on May 5, Ferrer and the European Pulmonary Hypertension Association (PHA Europe) have launched the PHantasticals campaign to raise public awareness about rare and chronic lung diseases like pulmonary hypertension (PH). The campaign features a collection of mermaid characters called the…

Chiesi Farmaceutici has acquired the worldwide rights to a number of investigational antibodies that may be able to treat pulmonary arterial hypertension (PAH) from the developer, Allinaire Therapeutics. All of the antibodies act against the endothelial monocyte-activating polypeptide (EMAP II), a pro-inflammatory molecule that is thought to…

Longer-term use of Ventavis (iloprost) as an add-on therapy significantly improved blood flow and lowered blood pressure in people with pulmonary arterial hypertension (PAH), a small study in Japan reported. Findings support this inhaled therapy’s established benefits as a pulmonary vasodilator — a medicine that  widens, or dilate,…

Infants born extremely premature — at 23 to 25 weeks of pregnancy — are at a high risk of developing pulmonary hypertension (PH) before they are 3 months old but can be helped with treatment, a recent study reported. Initial signs of disease, evident on echocardiographs in these infants,…

The Pulmonary Hypertension Association (PHA) will join more than 80 organizations around the world on May 5 to recognize World Pulmonary Hypertension (PH) Day. The event is intended to raise global awareness about PH, a rare, life-threatening disease that affects more than 75 million people worldwide and for which…

Treatment with DehydraTECH-CBD, Lexaria Bioscience’s investigational cannabis-derived treatment for pulmonary hypertension (PH), led to reduced pulmonary artery pressure in healthy volunteers who were exposed to low oxygen levels — especially among male participants — in conditions that mimicked PH. This was according to data from the now-completed HYPER-H21-3…

A four-week self-help intervention program — based on principles of cognitive-behavioral therapy (CBT), a type of talk therapy — significantly reduced anxiety and depression among people with pulmonary hypertension (PH), according to data from a small U.K. pilot study. “We developed a self-help intervention for anxiety in PH, which…

The Pulmonary Hypertension Association (PHA) is accepting nominations for its Outstanding Member Awards, which recognize individuals who show dedication to the pulmonary hypertension (PH) community. People with PH, their caregivers, friends, and doctors are invited to nominate “outstanding” PHA members for their “volunteer efforts in patient/caregiver support, advocacy,…